Musings on the H-W “safe harbor” and how it applies in the MNTA-Amphastar case: http://www.ipwatchdog.com/2012/08/07/momenta-pharmaceuticals-the-hatch-waxman-safe-harbor-widens-to-include-post-fda-approval-activity/id=27191/